Summary
NewLimit raises $130M in series B funding to extend human lifespan, co-founded by Coinbase CEO Brian Armstrong, develops treatments to reprogram liver cells, achieves promising early results
Key Points
The company is still a few years away from starting human trials, but aims to continue developing new anti-aging medicine using an AI model and then testing the most promising of these machine-generated drugs in its laboratory.
NewLimit's lab experiments demonstrate this rejuvenation can restore the cells' ability to process fat and alcohol, with the company measuring progress by contrasting how cells from a younger individual and an older person respond to substances.
The startup has three prototype medicines that reprogram liver cells, with Kimmel saying the data points from the experiment are then used to retrain the AI model in a process known as 'lab in a loop'.
Why It Matters
This funding round highlights NewLimit's progress in developing anti-aging treatments and its potential to extend human lifespan.
Author
Marina Temkin